Myeloma Clinical Trials in Madrid
35 recruitingMadrid, Spain
Showing 1–20 of 35 trials
Recruiting
Phase 3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Relapsed or Refractory Multiple Myeloma
Celgene810 enrolled266 locationsNCT05519085
Recruiting
Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Multiple Myeloma
Pfizer492 enrolled274 locationsNCT06152575
Recruiting
Phase 3
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Multiple MyelomaNewly Diagnosed Multiple Myeloma
GlaxoSmithKline520 enrolled181 locationsNCT06679101
Recruiting
Phase 2Phase 3
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Multiple Myeloma
AbbVie660 enrolled38 locationsNCT07095452
Recruiting
Phase 1
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Relapsed or Refractory Multiple MyelomaPreviously Treated Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC180 enrolled29 locationsNCT05652335
Recruiting
A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
Janssen Pharmaceutica N.V., Belgium300 enrolled87 locationsNCT05160584
Recruiting
Phase 2
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
Smoldering Multiple Myeloma (SMM)Monoclonal Gammopathy of Undetermined Significance (MGUS)
Regeneron Pharmaceuticals116 enrolled20 locationsNCT06140524
Recruiting
Phase 1Phase 2
A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
Multiple Myeloma
Hoffmann-La Roche200 enrolled16 locationsNCT05583617
Recruiting
Phase 3
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Multiple Myeloma
Pfizer944 enrolled238 locationsNCT05020236
Recruiting
Phase 1
A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma
Plasma Cell Myeloma Refractory
Sanofi87 enrolled19 locationsNCT06630806
Recruiting
Phase 3
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
Multiple Myeloma
European Myeloma Network B.V.1,000 enrolled59 locationsNCT06932562
Recruiting
Phase 1Phase 2
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Multiple MyelomaMyelodysplastic SyndromesLeukemia, Myeloid, Acute+1 more
Sumitomo Pharma America, Inc.606 enrolled104 locationsNCT04988555
Recruiting
Phase 3
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
Multiple Myeloma
Janssen Research & Development, LLC795 enrolled242 locationsNCT06208150
Recruiting
Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency
Multiple MyelomaSecondary Immunodeficiency (SID)
Takeda75 enrolled27 locationsNCT05879757
Recruiting
Phase 1
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Multiple MyelomaMyeloma
K36 Therapeutics, Inc.125 enrolled22 locationsNCT05651932
Recruiting
Phase 1Phase 2
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
Multiple Myeloma
AstraZeneca226 enrolled36 locationsNCT06106945
Recruiting
Phase 1Phase 2
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Bristol-Myers Squibb260 enrolled17 locationsNCT05372354
Recruiting
Phase 2
Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)
De Novo Multiple MyelomaAnitocabtagene Autoleucel
PETHEMA Foundation30 enrolled10 locationsNCT07045909
Recruiting
Phase 1Phase 2
A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
Chronic Lymphocytic Leukemia (CLL)High Grade B-Cell Lymphoma, Not Otherwise SpecifiedMultiple Myeloma (MM)+3 more
IDP Discovery Pharma S.L.37 enrolled11 locationsNCT05908409
Recruiting
Not Applicable
Cardiovascular Prevention Strategies in Elderly Patients With Cancer (CARTIER Clinical Trial)
CardiotoxicityCancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma)Elderly+1 more
Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León514 enrolled14 locationsNCT03711110